Table 4.
Trials targeting the STN region
| STN | ||||
|---|---|---|---|---|
| Reference | Responders (ratio) | Follow-up | Patients included elsewhere | Y-BOCS Reduction |
| Mallet, 2002 [43] | 2/2 | 6 months | 82.7% | |
| Fontaine, 2004 [44] | 1/1 | 6 months | 96.8% | |
| Mallet, 2008 [45] | 7/16 | 3 months | 37.8% | |
| Chabardès, 2012* [46] | 2/4 | 6 months | two patients from Mallet et al. [45] | 53.4% |
| Barcia, 2013 [37] | 2/2 | 3 months | 42.5% | |
| Mean | 57.1% | 45.3% | ||
STN: Subthalamic nucleus. Responders’ ratio: responders defined as 35% improvement in Y-BOCS score or more. Follow-up: latest follow-up reported. Patients included elsewhere: Number of patients of which the data has been reported before and corresponding publication. Y-BOCS reduction: mean reduction for new patients at latest follow-up or reduction range if individual data not available. *Data not included in pooled means due to duplicated data.